Marissa Natelson Love
Neurology · Birmingham, ALNPI 1760619134
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,725 of the $14,218 with a category attached, or 82.5%. Lilly USA, LLC accounts for 71.9% of it on its own, with 1 other manufacturer making up the rest. 2025 is the largest year on record at $10,218, 5.1 times the $2,000 reported in 2023.
Across 9 payments — averaging $1579.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$10K
- Curium US LLC$4K
Across 64 payments — averaging $12,160 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$466K
- Eli Lilly$312K
What the payments were for
- Consulting fees$11,72582%
- Speaking & faculty fees$2,00014%
- Food & beverage$4933%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 4 | $10,218 |
| Curium US LLC | 5 | $4,000 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KISUNLA$10,218
- Ioflupane I 123$2,000
How this compares
$14,218 in reported general payments places this provider in the 70th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 13 | $3,787 |
| Divalproex Sodium | 11 | $751 |
| Mirtazapine | 19 | $547 |
| Donepezil Hcl | 52 | $418 |
| Duloxetine Hcl | 22 | $396 |
| Escitalopram Oxalate | 21 | $282 |
| Citalopram HbrCitalopram Hydrobromide | 15 | $127 |
| Gabapentin | 21 | $124 |
| Baclofen | 12 | $81 |
| Clonazepam | 16 | $27 |
Paid to pharmacies, not to this prescriber.
Other neurology in Birmingham
- Diane CounceBirmingham$895K
- Emily RiserBirmingham$231K
- Wesley KingBirmingham$167K
- Jerzy SzaflarskiBirmingham$164K
- Victor SungBirmingham$138K
- Raymond FaughtBirmingham$99K
- David GeldmacherBirmingham$99K
- David StandaertBirmingham$82K
- Richard DiethelmBirmingham$65K
- Mina LobbousBirmingham$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.